Form 4: Twist Bioscience Exec Sells Shares for Tax Withholding

Emily M. Leproust, CEO of Twist Bioscience, sold 1,688 shares of common stock to cover tax withholding obligations related to vested Restricted Stock Units.

Summary

• Emily M. Leproust, Chief Executive Officer and Director of Twist Bioscience Corp., reported a transaction on June 22, 2026.
• The transaction involved the sale of 1,688 shares of common stock.
• These shares were sold at a price of $87.3224 per share.
• The sale was to cover tax withholding obligations arising from the vesting of Restricted Stock Units.
• This type of transaction is mandated by the company's equity incentive plans, requiring a 'sell to cover' to satisfy tax liabilities and does not represent a discretionary trade.
• Following this transaction, Leproust beneficially owns 842,919 shares of common stock directly.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing. While it involves a stock sale, it is clearly explained as a mandatory 'sell to cover' for tax purposes, not a discretionary sale, thus having minimal impact on sentiment.

Positives

• The transaction is a standard 'sell to cover' to satisfy tax obligations, indicating normal vesting and compensation realization rather than a strategic divestment.
• The reporting person, Emily M. Leproust, retains a significant beneficial ownership of 842,919 shares, demonstrating continued commitment to the company.

Negatives

• A sale of company stock, even for tax purposes, can sometimes be perceived negatively by the market if not clearly contextualized.

Risks

• The filing does not explicitly mention any new or emerging risks.
• The primary 'risk' is the potential for market misinterpretation of a 'sell to cover' transaction as a discretionary sale.

Future Outlook

No specific forward-looking statements or guidance are provided in this Form 4 filing, which solely reports a past transaction.

Management Comments

• "These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of a tax withholding obligation to be funded by a 'sell to cover' transaction and do not represent discretionary trades by the Reporting Person."

Industry Context

StockSavvy.ai notes that Form 4 filings are routine for executives and directors, especially concerning stock options and restricted stock units. The 'sell to cover' mechanism is a common practice to manage tax liabilities associated with equity compensation, particularly in the biotechnology sector where equity is a significant component of executive compensation.

Stakeholder Impact

• Shareholders: The transaction is a standard 'sell to cover' for tax withholding, not a discretionary sale, and therefore is unlikely to have a significant negative impact on shareholder perception. The reporting person retains substantial ownership.

Next Steps

• No specific future actions or milestones are detailed in this filing.

Key Dates

Keywords

Form 4, Insider Transaction, Stock Sale, Tax Withholding, Restricted Stock Units, Vesting, Twist Bioscience, TWST, Emily M. Leproust, CEO, Director, Beneficial Ownership